vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $47.3M, roughly 1.6× CIVISTA BANCSHARES, INC.). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 11.3%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
CIVB vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $75.5M |
| Net Profit | $15.0M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 31.7% | — |
| Revenue YoY | — | 27.7% |
| Net Profit YoY | 47.4% | — |
| EPS (diluted) | $0.72 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $75.5M | ||
| Q3 25 | $44.2M | $54.5M | ||
| Q2 25 | $41.4M | $52.4M | ||
| Q1 25 | $40.6M | $46.0M | ||
| Q4 24 | $40.4M | $59.1M | ||
| Q3 24 | $39.3M | $80.5M | ||
| Q2 24 | $38.1M | $47.1M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.8M | $8.8M | ||
| Q2 25 | $11.0M | $5.9M | ||
| Q1 25 | $10.2M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $8.4M | $20.3M | ||
| Q2 24 | $7.1M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | 22.7% | ||
| Q3 25 | 35.4% | 17.6% | ||
| Q2 25 | 31.1% | 12.7% | ||
| Q1 25 | 29.4% | 8.7% | ||
| Q4 24 | 28.2% | 22.6% | ||
| Q3 24 | 25.2% | 27.4% | ||
| Q2 24 | 21.2% | -4.6% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 28.9% | 16.2% | ||
| Q2 25 | 26.6% | 11.2% | ||
| Q1 25 | 25.0% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.3% | 25.2% | ||
| Q2 24 | 18.5% | -9.6% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $0.26 | ||
| Q3 25 | $0.68 | $0.17 | ||
| Q2 25 | $0.71 | $0.12 | ||
| Q1 25 | $0.66 | $0.06 | ||
| Q4 24 | $0.62 | $0.40 | ||
| Q3 24 | $0.53 | $0.41 | ||
| Q2 24 | $0.45 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $553.9M | $130.3M |
| Total Assets | $4.3B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $130.3M | ||
| Q3 25 | $499.0M | $115.3M | ||
| Q2 25 | $404.1M | $104.7M | ||
| Q1 25 | $397.4M | $97.1M | ||
| Q4 24 | $388.5M | $92.1M | ||
| Q3 24 | $394.4M | $71.1M | ||
| Q2 24 | $373.8M | $48.5M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $216.3M | ||
| Q3 25 | $4.1B | $202.9M | ||
| Q2 25 | $4.2B | $194.9M | ||
| Q1 25 | $4.1B | $196.2M | ||
| Q4 24 | $4.1B | $213.3M | ||
| Q3 24 | $4.1B | $220.7M | ||
| Q2 24 | $4.0B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $14.4M | ||
| Q3 25 | $19.0M | $9.7M | ||
| Q2 25 | $11.1M | $14.1M | ||
| Q1 25 | $3.6M | $3.6M | ||
| Q4 24 | $48.2M | $15.6M | ||
| Q3 24 | $12.9M | $11.0M | ||
| Q2 24 | $12.2M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | $3.5M | $3.6M | ||
| Q4 24 | $44.1M | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | 8.5% | 7.7% | ||
| Q4 24 | 109.1% | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | 0.4% | 0.1% | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | 1.10× | ||
| Q2 25 | 1.01× | 2.41× | ||
| Q1 25 | 0.36× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 0.54× | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
PBYI
Segment breakdown not available.
